In this study, we hypothesize that dasatinib inhibits HCC by modulating SFK/FAK/p130CAS, PI3K//PTEN/Akt/mTOR, Ras/Raf/MAPK and/or Stats signaling pathways. Here, BCAR1 is linked to hepatocellular carcinoma.